--- title: "Neoadjuvant Breast Cancer SWOG S2206 | Sutter Health" description: "Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) Plus Chemotherapy Versus Chemotherapy Alone for MammaPrint Ultrahigh (PM2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer" url: "https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-breast-swog-s2206-1049141944" --- 1. [Home](https://www.sutterhealth.org/) / 2. [Research](https://www.sutterhealth.org/research) / 3. [Clinical trials](https://www.sutterhealth.org/research/clinical-trials) / 4. Neoadjuvant Breast Cancer SWOG S2206 # Neoadjuvant Breast Cancer SWOG S2206 **Status:** Open to Enrollment [Email us to enroll](https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-breast-swog-s2206-1049141944#enroll) #### Study details View study details on [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06058377). #### Locations - Sutter Health System Wide #### Clinical trial FAQs Information for patients and study volunteers, including [frequently asked questions](https://www.sutterhealth.org/research/faqs). Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer. This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. ![Kristie A Bobolis, M.D.](https://dyn.mktgcdn.com/p/CJ3AD8rUK3dIMXhyG0Hk7UeScxen8-1oZfz4yDFpCEQ/fit=crop,gravity=auto,dpr=2,width=188,height=250,quality=100) Kristie A Bobolis, M.D. Principal investigator [View profile](https://www.sutterhealth.org/research/investigators/kristie-a-bobolis-md-1049681204) ## Sub-Investigators [Uma Suryadevara, M.D.](https://www.sutterhealth.org/research/investigators/uma-suryadevara-md-1049681015) , [Xin Li, M.D., Ph.D.](https://www.sutterhealth.org/research/investigators/xin-li-md-phd-1078064888) , [Kristin N Arreola, M.D.](https://www.sutterhealth.org/research/investigators/kristin-n-arreola-md-1049681025) , [Rajeswari Chellappah, M.D.](https://www.sutterhealth.org/research/investigators/rajeswari-chellappah-md-1049681022) , [Dron Gauchan, M.D.](https://www.sutterhealth.org/research/investigators/dron-gauchan-md-1049681200) , [Nitin Rohatgi, M.D., MBA](https://www.sutterhealth.org/research/investigators/nitin-rohatgi-md-mba-1049681017) ## Email us to enroll - [Email Sutter Health System Wide](mailto:ClinicalResearch%40sutterhealth.org?subject=More%20information%20on%20Neoadjuvant%20Breast%20Cancer%20SWOG%20S2206%20in%20Sutter%20Health%20System%20Wide&body=Please%20be%20aware%20that%20if%20you%20reply%20with%20unencrypted%20email%2C%20this%20increases%20the%20risk%20that%20information%20could%20be%20read%20by%20an%20unauthorized%20third%20party.%20Please%20do%20not%20include%20any%20Protected%20Health%20Information%20in%20your%20email%20response.) ## Related clinical trials [View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial) - Clinical trial ### [Adjuvant Breast Cancer A012103 OptimiCE-PCR](https://www.sutterhealth.org/research/clinical-trials/adjuvant-breast-cancer-a012103-optimice-pcr-1094794503) OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy With Checkpoint Inhibitor Therapy **Status:** Open to Enrollment - Clinical trial ### [Adjuvant Breast Cancer ER-pos/HER2-neg EA1242](https://www.sutterhealth.org/research/clinical-trials/adjuvant-breast-cancer-er-pos-her2-neg-ea1242-2072227055) A Phase III Trial of Rx Therapy Guided by Genomic Risk Assessment for High Anatomic Stage ER-pos/HER2-neg Breast Cancer With RS≤25 (RxFINE-Low) **Status:** Open to Enrollment - Clinical trial ### [Adjuvant Breast NRG-BR009](https://www.sutterhealth.org/research/clinical-trials/adjuvant-breast-nrg-br009-1049142000) A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 (OFSET) **Status:** Open to Enrollment - Clinical trial ### [Adjuvant Early Breast Cancer Giredestrant BO46775 kalitERA](https://www.sutterhealth.org/research/clinical-trials/adjuvant-early-breast-cancer-giredestrant-bo46775-kalitera-2100886500) A Phase IIIb, Single-arm, Open-Label, Multicenter Study Evaluating the Treatment Adherence, Tolerability, and Patient-Reported Outcomes of Giredestrant in Patients With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer **Status:** Coming Soon - Clinical trial ### [Adjuvant Triple NegativeBreast Cancer Ascent-05](https://www.sutterhealth.org/research/clinical-trials/adjuvant-triple-negative-breast-cancer-ascent-05-2022817141) A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy **Status:** Open to Enrollment [View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial) ```json {"@context":"https://schema.org","@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org","logo":"https://www.sutterhealth.org/static/images/sutter-health-logo.svg","address":{"@type":"PostalAddress","streetAddress":"2200 River Plaza Drive","addressLocality":"Sacramento","addressRegion":"CA","postalCode":"95833","addressCountry":"US"},"areaServed":{"@type":"AdministrativeArea","name":"California"},"sameAs":["https://www.facebook.com/SutterHealth","https://www.instagram.com/sutterhealth/","https://x.com/SutterHealth","https://www.youtube.com/sutterhealth","https://www.linkedin.com/company/sutter-health","https://en.wikipedia.org/wiki/Sutter_Health"]} ``` ```json {"@context":"https://schema.org","@type":"BreadcrumbList","@id":"https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-breast-swog-s2206-1049141944#breadcrumblist","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://www.sutterhealth.org/"},{"@type":"ListItem","position":2,"name":"Research","item":"https://www.sutterhealth.org/research"},{"@type":"ListItem","position":3,"name":"Clinical trials","item":"https://www.sutterhealth.org/research/clinical-trials"},{"@type":"ListItem","position":4,"name":"Neoadjuvant Breast Cancer SWOG S2206"}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalWebPage","@id":"https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-breast-swog-s2206-1049141944#medicalwebpage","name":"Neoadjuvant Breast Cancer SWOG S2206","description":"Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) Plus Chemotherapy Versus Chemotherapy Alone for MammaPrint Ultrahigh (PM2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer","url":"https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-breast-swog-s2206-1049141944","inLanguage":"en-US","dateModified":"2026-06-01","publisher":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"},"medicalAudience":{"@type":"MedicalAudience","audienceType":"Patient"},"mainEntity":{"@id":"https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-breast-swog-s2206-1049141944#medicaltrial"},"breadcrumb":{"@id":"https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-breast-swog-s2206-1049141944#breadcrumblist"},"mentions":[{"@type":"Person","name":"Kristie A Bobolis, M.D.","url":"https://www.sutterhealth.org/research/investigators/kristie-a-bobolis-md-1049681204","jobTitle":"Principal Investigator","affiliation":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"}}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalTrial","@id":"https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-breast-swog-s2206-1049141944#medicaltrial","name":"Neoadjuvant Breast Cancer SWOG S2206","alternateName":"Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) Plus Chemotherapy Versus Chemotherapy Alone for MammaPrint Ultrahigh (PM2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer","url":"https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-breast-swog-s2206-1049141944","description":"Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer. This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer.","identifier":"NCT06058377","code":{"@type":"MedicalCode","codeValue":"NCT06058377","codingSystem":"ClinicalTrials.gov"},"sameAs":"https://clinicaltrials.gov/study/NCT06058377","status":"https://schema.org/Recruiting","healthCondition":[{"@type":"MedicalCondition","name":"Breast Cancer"}],"studyLocation":[{"@type":"AdministrativeArea","name":"Sutter Health System Wide"}]} ```